In this video interview, Dr Shilpa Gupta, assistant professor, Haematology, Oncology and Transplantation Division, University of Minnesota, USA, discusses combining VEGF inhibitors with immunotherapy for patients with kidney cancer. Since kidney cancer is a VEGF-driven disease, it makes sense to combine VEGF inhibitors, such as sunitinib or axitinib, with immunotherapy drugs, such as nivolumab or pembrolizumab. There is currently a trial investigating a combination of axitinib (Inlyta) with pembrolizumab (Keytruda) in the first-line setting for kidney cancer.

See more here